In August 2026, as the Fed’s rate hike cycle neared its end, demand for defensive investments continued to rise. Among various investment sectors, high-dividend pharma, with its high dividends, stable cash flow, and AI-driven transformation potential, became a focal point for investors. On August 20, global pharmaceutical giant Eli Lilly released its Q3 2026 fiscal report (ending June 30, 2026), showing strong core business performance: Zepbound revenue up 45% again, dividend raised for 9th consecutive year (8%), and accelerated AI drug R&D, offering investors a balanced defensive and growth-oriented opportunity.
Eli Lilly Q3 Earnings Core Data: Weight Loss Drugs and AI Drugs as Dual Drivers
According to Eli Lilly’s report, in Q3 2026 fiscal year, revenue reached $28.5 billion, up 12% YoY; net profit was $6.8 billion, up 15% YoY. Among these, Zepbound (tirzepatide) revenue hit $8.5 billion, up 45% YoY, becoming the core driver of revenue growth. Additionally, the company announced raising quarterly dividend from $1.15 to $1.24 per share, with an annualized yield of ~2.8%, marking the 9th consecutive year of dividend growth, further strengthening its high-dividend attribute.
Weight Loss Drug Business: Zepbound Continues to Scale, Revenue Up 45% Again
Eli Lilly’s weight loss drug business has been the brightest spot in recent years. Since its 2023 launch, Zepbound, with its effective weight loss (average 15%-20% reduction) and broad indications (including obesity, type 2 diabetes), quickly captured the market. In Q3 2026, Zepbound sales in the U.S. reached $6 billion, up 50% YoY; in Europe, $1.5 billion, up 35% YoY; in Asia-Pacific (especially China), $1 billion, up 40% YoY. Despite competition from Novo Nordisk’s Wegovy, Zepbound maintained strong growth momentum due to lower side effects (e.g., gastrointestinal reactions) and more flexible dosing (once weekly).
Market analysts note that the penetration rate of the weight loss drug market remains low. Industry data shows ~650 million obese patients globally, with less than 10% receiving weight loss drug treatment. As insurance coverage expands (e.g., some U.S. states have included weight loss drugs in insurance) and patient awareness rises, the market still has huge growth potential. Eli Lilly expects Zepbound sales to exceed $15 billion in 2027, becoming its top revenue source.
Dividend Raised for 9th Consecutive Year: High-Dividend Attribute Strengthens Defensive Value
At the end of the rate hike cycle, the defensive value of high-dividend stocks is prominent. Since 2018, Eli Lilly has raised dividends for 9 consecutive years, with a CAGR of ~6%. This 8% increase not only reflects stable cash flow (operating cash flow of $18 billion in Q1-Q3 2026 fiscal year) but also management’s confidence in the future. For investors, high dividends mean stable cash returns, while the company’s investment in AI drug R&D provides growth momentum, achieving a balance between “defensive” and “growth”.
Notably, Eli Lilly’s dividend yield (~2.8%) is higher than the S&P 500’s average (~1.5%), and its payout ratio (30% of net profit) is reasonable, with room for future increases. Analysts expect dividend growth to maintain 5%-8% annually as revenue continues to grow.
AI Pharma: Eli Lilly’s New Growth Engine
Beyond weight loss drugs, Eli Lilly is accelerating AI drug R&D to improve efficiency and reduce costs via technological innovation. In 2026, its AI pharma investment reached $2.5 billion, up 30% YoY, accounting for 40% of total R&D spending. The company built a complete AI drug R&D system through acquisitions (e.g., AI drug discovery platform Insilico Medicine in 2025), tech partnerships (e.g., with NVIDIA to develop AI drug design platforms), and internal AI teams.
Opportunities and Challenges in AI Pharma
The core advantage of AI pharma is shortening R&D cycles and reducing costs. Traditional drug R&D takes 10-15 years and costs up to $2 billion, while AI can cut cycles to 5-8 years and reduce costs by 30%-50%. Eli Lilly has shortened R&D cycles for multiple drug candidates by 2-3 years via AI platforms. For example, its AI-driven diabetes drug “Lilly-001” entered Phase II trials, expected to launch in 2028, 3 years ahead of traditional paths.
However, AI pharma faces challenges. First, data quality: AI models require large volumes of high-quality clinical data, which Eli Lilly addressed by acquiring medical data companies (e.g., Flatiron Health in 2024). Second, regulatory uncertainty: the FDA is still exploring AI drug R&D processes, and Eli Lilly ensures compliance through close collaboration with the FDA.
Industry Analysis: Balance of Defensive and Growth in High-Dividend Pharma
High-dividend pharma refers to pharmaceutical companies with high dividends, stable cash flow, and active adoption of AI technology. In the current market, these companies have the following advantages:
- Defensive: High dividends mean stable cash returns, suitable for holding during the end of rate hikes or increased economic uncertainty. Eli Lilly’s 9-year dividend growth and reasonable payout ratio provide good defensiveness.
- Growth: New businesses like AI pharma and weight loss drugs offer growth momentum. Zepbound revenue continues to grow, and AI drug pipelines advance, with revenue expected to maintain >10% growth in the coming years.
- Valuation Advantage: Compared to tech stocks, pharma stocks have lower valuations (Eli Lilly’s P/E ~18x, vs. NVIDIA’s 35x) but similar growth potential, offering high cost-performance.
Compared to other high-dividend pharma companies, Eli Lilly’s advantage lies in its leading weight loss drug business and AI pharma layout. Merck, though with high dividends (50-year consecutive growth), has weaker weight loss drug positioning; Pfizer invests less in AI pharma, relying more on traditional drugs. Eli Lilly balances both, making it a high-quality target in high-dividend pharma.
Investor Focus: Dividend Yield and AI Pipeline Progress
For investors, two key metrics for Eli Lilly are dividend yield and AI drug pipeline progress. Dividend yield reflects defensiveness, while pipeline progress determines growth. Additionally, weight loss drug market share (e.g., whether Zepbound’s U.S. share exceeds Wegovy) is also important.
Analysts expect Eli Lilly’s 2027 revenue to reach $120 billion, net profit $30 billion, dividend yield to rise to 3.2%, and 2-3 AI drug candidates to enter Phase III trials. These factors will support its stock price to rise 15%-20% in the next 12 months.
Conclusion: Eli Lilly as a High-Quality Target in High-Dividend Pharma
Eli Lilly’s Q3 report shows its weight loss drug business continues to scale, dividend raised for 9th consecutive year, and AI pharma layout accelerates, making it a high-quality defensive and growth-oriented target in high-dividend pharma. At the end of the rate hike cycle, investors need companies that offer stable cash returns and growth from tech dividends, and Eli Lilly is such a choice. For long-term investors, holding Eli Lilly not only provides dividend income but also shares growth dividends from AI pharma and weight loss drugs.
